Travere’s Sparsentan Faces Slower Uptake Due To Liver Monitoring Requirement
Firm Thinks Unmet Need Will Ensure Commercial Success
The FDA required an updated REMS for liver monitoring out of caution over potential liver toxicity, though the drug has not caused drug-induced liver injury in development to date.
